Evidence map›Paper›PMID 31186064›Full record

ArticleJournal of experimental & clinical cancer research : CR2019

Inhibition of the aberrant A1CF-FAM224A-miR-590-3p-ZNF143 positive feedback loop attenuated malignant biological behaviors of glioma cells.

Yichen Song, Lianqi Shao, Yixue Xue, Xuelei Ruan, Xiaobai Liu, Chunqing Yang, Jian Zheng, Shuyuan Shen, Jiajia Chen, Zhen Li and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. APOBEC-1 Complementation Factor: From RNA Binding to Cancer.Cancer control : journal of the Moffitt Cancer Center
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Yichen SongDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Lianqi ShaoDepartment of Neurobiology, School of Life Sciences, China Medical University, Shenyang, 110122, China.
Yixue XueDepartment of Neurobiology, School of Life Sciences, China Medical University, Shenyang, 110122, China.
Xuelei RuanDepartment of Neurobiology, School of Life Sciences, China Medical University, Shenyang, 110122, China.
Xiaobai LiuDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Chunqing YangDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Jian ZhengDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Shuyuan ShenDepartment of Neurobiology, School of Life Sciences, China Medical University, Shenyang, 110122, China.
Jiajia ChenDepartment of Neurobiology, School of Life Sciences, China Medical University, Shenyang, 110122, China.
Zhen LiDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Yunhui LiuDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China. liuyh_cmuns@163.com.
China Medical University · CN

Funding

Liaoning Science and Technology Plan Project No.2017225020, 2015225007National Natural Science Foundation of China 81872073, 81872503, 81672511 and 81573010outstanding scientific fund of Shengjing hospital No. 201304Project of Key Laboratory of Neuro-oncology in Liaoning Province 112-2400017005special developmental project guided by central government of Liaoning Province No. 2017011553-301
6 · The paper itself

Abstract

backgroundGlioma is the most common and lethal type of malignant brain tumor. Accumulating evidence has highlighted that RNA binding protein APOBEC1 complementation factor (A1CF) is involved in various cellular processes by modulating RNA expression, and acts as an oncogene in breast cancer. However, the function of A1CF in glioma remained unclear.

methodsQuantitative RT-PCR and western blot analysis were employed to detect the expression levels of A1CF, lncRNA family with sequence similarity 224 member A (FAM224A), miR-590-3p, zinc finger protein 143 (ZNF143) and ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 (ASAP3) in glioma tissues and cell lines. The Cell Counting Kit-8 assay, migration and invasion assays, and flow cytometry analysis were conducted to evaluate the function of A1CF, FAM224A, miR-590-3p, ZNF143 and ASAP3 in the malignant biological behaviors of glioma cells. Moreover, luciferase reporter, RIP and ChIP assays were used to investigate the interactions among A1CF, FAM224A, miR-590-3p, ZNF143, ASAP3 and MYB. Finally, the xenograft tumor growth assay further ascertained the biological roles of A1CF, FAM224A and miR-590-3p in glioma cells.

resultsA1CF was upregulated and functioned as an oncogene via stabilizing and increasing FAM224A expression; moreover, high A1CF and FAM224A expression levels indicated a poorer prognosis for glioma patients. Conversely, miR-590-3p was downregulated and exerted a tumor-suppressive function in glioma cells. Inhibition of A1CF significantly restrained cell proliferation, migration and invasion, and promoted apoptosis by upregulating miR-590-3p in a FAM224A-dependent manner. FAM224A was a molecular sponge of miR-590-3p and they were in an RNA-induced silencing complex. ZNF143 was upregulated in glioma tissues and cell lines. MiR-590-3p could negatively modulate the expression of ZNF143 via binding to the ZNF143 3' UTR. Moreover, ZNF143 participated in miR-590-3p-induced tumor-suppressive activity on glioma cells. ASAP3 and MYB were transcriptionally activated by ZNF143, and importantly, ZNF143 could directly target the promoter of FAM224A and stimulate its expression, collectively forming a positive feedback loop.

conclusionsThe present study clarifies that the A1CF-FAM224A-miR-590-3p-ZNF143 positive feedback loop conducts critical regulatory effects on the malignant progression of glioma cells, which provides a novel molecular target for glioma therapy.

Indexed as

Gene Expression Regulation, NeoplasticRNA Interference3' Untranslated RegionsAnimalsApoptosisCell Line, TumorCell MovementCell ProliferationDisease Models, AnimalGene SilencingGenes, ReporterGliomaHeterograftsHumansMiceMicroRNAs3' Untranslated RegionsA1CF protein, humanMicroRNAsMIRN590 microRNA, humanNeoplasm ProteinsRNA-Binding ProteinsTrans-ActivatorsZNF143 protein, humanA1CFASAP3FAM224AGliomaLncRNAsmiR-590-3pZNF143

Identifiers

PMID31186064
PMCPMC6558706
OpenAlexW2952751640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.